References
1. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global
prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic
review and meta-analysis. Blood cells, molecules & diseases.2009;42(3):267-278.
2. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase
deficiency. Lancet (London, England). 2008;371(9606):64-74.
3. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group.Bulletin of the World Health Organization. 1989;67(6):601-611.
4. Robinson KM, Yang W, Haidar CE, et al. Concordance between
glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and
rasburicase use in patients with hematologic malignancies. The
pharmacogenomics journal. 2019;19(3):305-314.
5. Relling MV, McDonagh EM, Chang T, et al. Clinical Pharmacogenetics
Implementation Consortium (CPIC) guidelines for rasburicase therapy in
the context of G6PD deficiency genotype. Clinical pharmacology and
therapeutics. 2014;96(2):169-174.
6. Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support
of treatment and elimination of malaria: recommendations for evaluation
of G6PD tests. Malaria journal. 2013;12:391.
7. Echler G. Determination of glucose-6-phosphate dehydrogenase levels
in red cell preparations. The American journal of medical
technology. 1983;49(4):259-262.
8. Lakomek M, Schröter W, De Maeyer G, Winkler H. On the diagnosis of
erythrocyte enzyme defects in the presence of high reticulocyte counts.British journal of haematology. 1989;72(3):445-451.
9. Morelli A, Benatti U, Lenzerini L, et al. The interference of
leukocytes and platelets with measurement of clucose-6-phosphate
dehydrogenase activity of erythrocytes with low activity variants of the
enzyme. Blood. 1981;58(3):642-644.
10. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase
deficiency. Blood. 2020;136(11):1225-1240.
11. Robinson K, Yang W, Karol S, et al. No evidence that G6PD deficiency
affects the efficacy or safety of daunorubicin in acute lymphoblastic
leukemia induction therapy. Pediatric Blood & Cancer. 2019;66.
12. Kornberg A, Horecker BL. Glucose-6-Phosphate Dehydrogenase. IN
Methods in Enzymology. 1955;1:323.
13. Lohr GW, Waller HD. Glucose-6-Phosphate Dehydrogenase. IN
Methods of Enzymatic Analysis. 1974:636.
14. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G.
Recommendations for the transfusion of red blood cells. Blood
Transfus. 2009;7(1):49-64.
15. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the
clinical implementation of pre-emptive pharmacogenetics. American
journal of medical genetics Part C, Seminars in medical genetics.2014;166C(1):45-55.
16. Standardization of procedures for the study of glucose-6-phosphate
dehydrogenase. Report of a WHO Scientific Group. World Health
Organization technical report series. 1967;366:1-53.
17. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo
E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review
of the ”old” and update of the new mutations. Blood cells,
molecules & diseases. 2012;48(3):154-165.
18. Town M, Bautista JM, Mason PJ, Luzzatto L. Both mutations in G6PD A-
are necessary to produce the G6PD deficient phenotype. Human
molecular genetics. 1992;1(3):171-174.
19. Youngster I, Arcavi L, Schechmaster R, et al. Medications and
Glucose-6-Phosphate Dehydrogenase Deficiency. Drug Safety.2010;33(9):713-726.
20. Luzzatto L, Seneca E. G6PD deficiency: a classic example of
pharmacogenetics with on-going clinical implications. British
journal of haematology. 2014;164(4):469-480.
21. St. Jude Children’s Research Hospital. Glucose-6-Phosphate
Dehydrogenase (G6PD). http://stjude.org/g6pd. Accessed August 20, 2020.
22. Bansal V, Libiger O. Fast individual ancestry inference from DNA
sequence data leveraging allele frequencies for multiple populations.BMC bioinformatics. 2015;16:4.
23. Van Driest SL, Shi Y, Bowton EA, et al. Clinically Actionable
Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing.Clinical Pharmacology & Therapeutics. 2014;95(4):423-431.